Department of Neurology, University of Kentucky, 740 South Limestone KY Clinic, J401, Lexington, KY, 40536, USA.
The Department of Veterans Affairs Lexington VA Medical Center, Troy Bowling Campus, Lexington, KY, USA.
Curr Neurol Neurosci Rep. 2020 Apr 15;20(5):10. doi: 10.1007/s11910-020-01031-9.
The polypill, referring to a variety of combinations of low-cost cardiovascular and stroke preventive medications combined in a single tablet, has been evaluated as a population-based approach for cardiovascular disease prevention in several trials. This review summarizes the scope of the problem, main trial results, and their potential applicability to the US population.
Initial trials demonstrated the efficacy of the polypill approach. The most recent, the PolyIran study, showed the effectiveness of one form of a polypill for cardiovascular disease prevention, high medication adherence, and low adverse event rates. None of published polypill trials focused on stroke as the primary outcome and most were conducted in developing countries, limiting generalization to the US population. A US-based randomized trial with stroke as the primary outcome is needed to assess the usefulness of this approach for stroke prevention in the USA.
复方药，指的是将多种低成本的心血管疾病和中风预防药物组合在一片药片中，已经在多项试验中被评估为一种基于人群的心血管疾病预防方法。本文综述总结了该问题的范围、主要试验结果及其对美国人群的潜在适用性。
最初的试验证明了复方药方法的有效性。最近的 PolyIran 研究表明，一种复方药形式对心血管疾病预防有效，药物依从性高，不良反应率低。已发表的复方药试验都没有将中风作为主要终点，而且大多数试验都在发展中国家进行，这限制了其在美国人群中的推广。需要在美国进行一项以中风为主要终点的随机试验，以评估这种方法在预防美国中风方面的有效性。
